


---

<b>Product Name</b>	:	ALTA-2618
<b>Cat. No.</b>	:	PC-25099
<b>CAS No.</b>	:	3034255-93-8
<b>Molecular Formula</b>	:	C <sub>33</sub> H <sub>28</sub> FN <sub>11</sub>
<b>Molecular Weight</b>	:	597.66
<b>Target</b>	:	Akt
<b>Solubility</b>	:	10 mM in DMSO



CAS: 3034255-93-8

## Biological Activity

Tanerasertib (ALTA-2618) is a potent, highly mutant-selective, allosteric **AKT1 E17K** inhibitor with EC<sub>50</sub> of 7 nM, 22-fold selectivity over WT AKT1 and 140-fold selectivity over WT AKT2.

ALTA-2618 demonstrated covalent attachment to the AKT1 E17K protein.

ALTA-2618 induced tumor regressions in AKT1 E17K mutant HR+/HER2low breast cancer, TNBC, and endometrial cancer PDXs at doses as low as 10 mg/kg/d.

## References

Eric A. Murphy, et al. **Cancer Res** (2024) 84 (7\_Supplement): LB173.

Patent WO2024073371 A1.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: [tech@probechem.com](mailto:tech@probechem.com)

---